COMMUNIQUÉS West-GlobeNewswire

Trading in GN Store Nord shares by board members, executives and associated persons

05/05/2025 - 11:30

GN Store Nord has received notification pursuant to article 19 of regulation (EU) no. 596/2014 of the below transactions related to shares in GN Store Nord made by persons discharging managerial responsibilities in GN [...]

Aclarion Welcomes Advocate Health as CLARITY Trial Site

05/05/2025 - 12:00

Advocate Health actively participates in research studies and is an innovator in technology, including spine The CLARITY trial is designed to demonstrate Nociscan’s ability to improve surgical outcomes for chronic low [...]

Recursion Reports First Quarter 2025 Financial Results and Provides Business Update

05/05/2025 - 12:00

Pipeline: Delivered on our commitment to a more focused R&D strategy by advancing a streamlined portfolio of 5+ clinical and preclinical programs in oncology and rare disease, while deprioritizing 3 clinical [...]

RetinalGenix Technologies, Inc. Announces Laboratory Lease Agreement with Life Science Incubator MBC BioLabs

05/05/2025 - 12:15

Company to use facility to further development of RetinalGenix’s therapies for neurodegenerative and retinal diseases APOLLO BEACH, Fla., May 05, 2025 (GLOBE NEWSWIRE) -- RetinalGenix Technologies, Inc. (OTCQB:RTGN) (“ [...]

Best Premature Ejaculation Pills: Treatment, Meaning, How to Treat, What is Premature Ejaculation, Early Ejaculation Problem, How To Avoid Quick Discharge Of Sperm, Causes (Performer 8)

05/05/2025 - 12:16

Glasgow, May 05, 2025 (GLOBE NEWSWIRE) -- 2025: Introduction Performer 8 is a reliable dietary supplement designed to enhance testosterone levels and improve male sexual health. Many men have reported positive outcomes [...]

BioNTech Announces Appointment of Ramón Zapata to Management Board as Chief Financial Officer

05/05/2025 - 12:30

Mainz, Germany, May 5, 2025 (GLOBE NEWSWIRE) – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) announced today that the Supervisory Board has appointed Ramón Zapata-Gomez to the Management Board as Chief [...]

Integra LifeSciences Reports First Quarter 2025 Financial Results

05/05/2025 - 12:30

PRINCETON, N.J., May 05, 2025 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, today reported financial results for the first quarter ending [...]

Best Male Fertility Supplements: Best Vitamin Supplements For Male Fertility And Male Conception, Fertilaid For Men, Best Sperm Motility Supplement, Best Coq10 For Male Fertility (Semenoll)

05/05/2025 - 12:43

Glasgow, May 05, 2025 (GLOBE NEWSWIRE) -- Boosting Male Fertility Naturally: Diet, Lifestyle & Supplements Having a diet rich in vitamins and minerals—along with a healthy lifestyle that includes proper sleep, [...]

BioNTech Announces First Quarter 2025 Financial Results and Corporate Update

05/05/2025 - 12:45

Continued oncology pipeline advancement with a strategic focus on two priority pan-tumor programs: next-generation immunomodulator BNT327, a bispecific antibody targeting PD-L1 and VEGF-A 1 , and mRNA cancer [...]

Vyvamind Under Review: Does Vyvamind Work? Best Adderall Alternative Nootropic Supplement

05/05/2025 - 12:47

Is Vyvamind the best Adderall alternative? Discover how this natural nootropic supplement boosts focus, energy, and mental clarity—backed by science and real reviews. Albany, New York, May 05, 2025 (GLOBE NEWSWIRE) -- [...]

Ocular Therapeutix™ Reports First Quarter 2025 Results and Business Highlights

05/05/2025 - 13:00

AXPAXLI™ SOL trials for wet AMD progressing rapidly following recent updates to accelerate and enhance the registrational program Following positive FDA feedback for potential AXPAXLI NPDR registrational trial, Ocular [...]

Eupraxia Pharmaceuticals Announces Sustained Positive Treatment Outcomes in Patients with Eosinophilic Esophagitis (EoE) After Nine Months of Receiving EP-104GI

05/05/2025 - 13:00

Eupraxia continues to observe positive treatment outcomes in its ongoing Phase 1b/2a trial, including for the first time clinical responses measured 9 months after dosing with EP-104GI At 9 months active drug continued [...]

Aptose Provides Clinical Update for the Tuspetinib-based Triple Drug Frontline Therapy in Newly Diagnosed AML Patients from the Phase 1/2 TUSCANY Trial

05/05/2025 - 13:00

Aptose is developing TUS+VEN+AZA as a one-of-a-kind safe and mutation agnostic frontline triple drug therapy for newly diagnosed AML patients First two dose cohorts of TUS+VEN+AZA triplet demonstrate safety, complete [...]

Foghorn Therapeutics to Participate in the Citizens Life Sciences Conference

05/05/2025 - 13:00

CAMBRIDGE, Mass., May 05, 2025 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal [...]

Aquestive Therapeutics to Participate in Citizens Life Sciences Conference

05/05/2025 - 13:00

WARREN, N.J., May 05, 2025 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives [...]

Ichnos Glenmark Innovation (IGI) Receives U.S. FDA Fast Track Designation for ISB 2001 for Relapsed/Refractory Multiple Myeloma

05/05/2025 - 13:00

Results from the dose-escalation portion of the Phase 1 clinical study of ISB 2001 in patients with heavily pretreated multiple myeloma to be presented at the 2025 ASCO Annual Meeting NEW YORK, May 05, 2025 (GLOBE [...]

Microbix’s Clot-Buster Drug Project Advances

05/05/2025 - 13:00

Sequel Pharma Executes Agreement with CDMO for Drug Product Manufacturing MISSISSAUGA, Ontario, May 05, 2025 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. ( TSX: MBX, OTCQX: MBXBF, Microbix® ), a life sciences innovator [...]

Kamada Announces Launch of a Comprehensive Post-Marketing Research Program for CYTOGAM®

05/05/2025 - 13:00

Program A imed at G enerating K ey D ata in S upport of the B enefits of CYTOGAM® in the Management of Cytomegalovirus ( CMV ) in Solid Organ Transplantation A Total of 10 Studies will be Conducted in Collaboration with [...]

Teva and Alvotech Announce FDA Approval of Interchangeability for SELARSDI™ (ustekinumab-aekn) with Stelara® (ustekinumab)

05/05/2025 - 13:00

The U.S. FDA has approved SELARSDI ™ (ustekinumab- aekn ) as interchangeable with the reference biologic Stelara ® (ustekinumab) in all presentations matching the reference product , effective as of April 30, 2025 [...]